Asymchem Laboratories (06821) will grant 3.8795 million shares according to the 2026 H-share plan.

19:00 01/09/2026

Nantong Yangzi River Investment Holdings Limited (06821) announced that on September 1, 2026, a total of 3,879,500 incentive shares will be granted under the 2026 H-share scheme, of which 2,144,000 incentive shares will be granted to connected persons of the Company (related grants), including four directors and directors or senior executives of the Company's subsidiaries; and 1,735,500 incentive shares will be granted to employees of the Group who are not connected persons of the Company (non-related grants, collectively referred to as "the grants" together with related grants).

Asymchem Laboratories (06821) announced that on September 1, 2026, a total of 3,879,500 incentive shares will be granted under the 2026 H share scheme, of which 2,144,000 incentive shares will be granted to connected persons of the company (connected grants), including four directors and directors or senior executives of the company's subsidiaries; and 1,735,500 incentive shares will be granted to employees of the Group who are not connected persons of the company (non-connected grants, collectively referred to as "grants" with connected grants).

OCUMENSION-B (01477): The drug registration application for dexamethasone ophthalmic suspension injection produced domestically has been accepted.

CHICMAX (02145) spent HKD 12.8414 million on September 1 to repurchase 575,000 shares.

REGENT PACIFIC (00575) has received a net milestone payment of $4.5 million from Fosun.

OCUMENSION-B (01477): The drug registration application for dexamethasone ophthalmic suspension injection produced domestically has been accepted.

CHICMAX (02145) spent HKD 12.8414 million on September 1 to repurchase 575,000 shares.

REGENT PACIFIC (00575) has received a net milestone payment of $4.5 million from Fosun.